Bon Natural Life Limited (BON) Fair Value & Analysis

Basic Materials · US · Market cap $12.4M

Below-average quality, screening 137% undervalued on our models.

What matters now

• The large discount to fair value meets weak quality (6/100). That raises the risk this is a value trap rather than a bargain.
• The price is below even our cautious bear case ($1.67). The market is more pessimistic than our downside scenario.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range ($1.67 to $3.16) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.

How to read this chart

60‑month range $1.05 – $3,828 · fair‑value band $1.67 – $3.16 · the $1.07 price screens below the $2.53 fair value. Dashed = 300-day average. As of Jul 15, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Bon Natural Life Limited (BON) currently trades at $1.07, while our model-based Fair Value estimate is $2.53, implying the stock looks roughly 136.7% undervalued today. The Quality Score stands at 6/100 (below-average quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Over the trailing twelve months, Bon Natural Life Limited generated revenue of $18.7M at a net margin of -10.7%. Revenue declined 21.9% year over year. It earns a return on equity of -4.0%. Net debt stands at $6.1M. Fundamentals as of Jul 15, 2026

Our scenario range runs from $1.67 (bear case) to $3.16 (bull case); at $1.07, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 54% below its 52-week high, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at 137%, BON screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Bon Natural Life Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China, Europe, North America, and the Middle East.

Full company description

Bon Natural Life Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China, Europe, North America, and the Middle East. The company offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. It sells its products through direct distributors. The company serves manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company has a strategic partnership with Tigerbone Group Limited. Bon Natural Life Limited was founded in 2006 and is headquartered in Xi'an, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Bon Natural Life Limited reported revenue of $18.7M in FY2025 versus $25.5M in FY2021, a compound −7.5%/yr. Reported net income was −$2.0M in FY2025.

Watch BON: get an alert when its fair value changes →

Peer Group

Specialty Chemicals · 673 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Specialty Chemicals median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).

Explore undervalued stocks

More undervalued Basic Materials stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.